Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Group 1 - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. concerning potential securities fraud or unlawful business practices by the company and its officers [2][4] - Iovance reported a significant decline in quarterly total product revenue for Q1 2025, amounting to $49.3 million, down from $73.7 million in the previous quarter [4] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [4] Group 2 - Following the release of the financial results and guidance revision, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [4] - Investors have until July 14, 2025, to request to be appointed as Lead Plaintiff in the class action if they purchased Iovance securities during the Class Period [2]

Core Viewpoint - A securities class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly making false or misleading statements regarding its business operations and the commercialization of its product, Amtagvi, leading to significant financial losses for investors [1][3]. Company Overview - Iovance is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumor cancers [2]. - The company's primary product, Amtagvi, is a tumor-derived autologous T-cell immunotherapy approved by the FDA on February 16, 2024, and launched commercially on February 20, 2024 [2]. Allegations in the Class Action - The lawsuit claims that during the class period, Iovance's management failed to disclose critical issues, including: - New Authorized Treatment Centers (ATCs) faced longer timelines to begin patient treatments with Amtagvi [3]. - Ineffectiveness of the sales team and ATCs in identifying and selecting patients, resulting in higher patient drop-off rates [3]. - These issues led to increased costs and reduced revenue as ATCs could not keep up with the manufactured product [3]. - Consequently, the positive statements made by the defendants regarding the company's business and prospects were materially misleading [3]. Financial Impact - On May 8, 2025, Iovance reported a significant decline in its 1Q25 total product revenue, which was $49.3 million, down from $73.7 million in the previous quarter [4]. - The company also revised its FY25 total product revenue guidance from a range of $450 million to $475 million down to $250 million to $300 million, citing recent launch dynamics of Amtagvi [4]. - Following this announcement, Iovance's share price dropped by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, amid unusually high trading volume [4].

Group 1 - The DJS Law Group is reminding investors of a class action lawsuit against Iovance Biotherapeutics, Inc. for violations of federal securities laws [1] - Shareholders who purchased Iovance's securities between May 9, 2024, and May 8, 2025, are encouraged to contact the firm before July 14, 2025 [1] - The lawsuit alleges that Iovance made false and misleading statements regarding the timelines for treatment with Amtagvi and the effectiveness of its sales team and Authorized Treatment Centers [2] Group 2 - The complaint indicates that the failure to effectively select patients for Amtagvi led to patient drop-off, resulting in lower revenues and higher costs for the company [2] - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns [4]

Core Viewpoint - Iovance Biotherapeutics, Inc. announced the five-year follow-up results of the Phase 2 C-144-01 clinical trial for Amtagvi® (lifileucel), showing significant long-term benefits in patients with advanced melanoma, including durable responses and meaningful overall survival rates [2][4][6]. Group 1: Clinical Trial Results - The five-year analysis of the C-144-01 trial included 153 patients and demonstrated unprecedented durability in advanced melanoma patients previously treated with anti-PD-1 and targeted therapies [3][4]. - The objective response rate was 31.4%, with a median time to response of 1.4 months and a median duration of response of 36.5 months [4]. - Nearly one third of responders (31.3%) maintained ongoing responses at the five-year assessment, with a median overall survival (mOS) of 13.9 months and a five-year survival rate of 19.7% [4]. Group 2: Safety Profile - The safety profile of Amtagvi was consistent with nonmyeloablative lymphodepletion and interleukin-2 administration, with no new or late-onset adverse events reported at a median follow-up of 57.8 months [5][6]. - The incidence of adverse events decreased rapidly within the first two weeks after Amtagvi infusion [5]. Group 3: Regulatory Approval and Future Trials - In February 2024, the FDA granted accelerated approval to Amtagvi for treating adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody [6]. - Iovance is conducting the TILVANCE-301 Phase 3 trial in frontline advanced melanoma to confirm the clinical benefit of Amtagvi [6][7]. Group 4: Company Overview - Iovance Biotherapeutics aims to be a leader in developing tumor infiltrating lymphocyte therapies, with Amtagvi being the first FDA-approved T cell therapy for a solid tumor indication [16]. - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve patient outcomes [16].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the July 14, 2025 deadline [2]. Group 2: Allegations Against Iovance - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to longer timelines and higher patient drop-offs [3]. - It is claimed that these issues resulted in increased costs and lower revenue for Iovance, as ATCs could not keep pace with the manufactured product, contradicting the company's positive statements about its business and prospects [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including securing over $438 million for investors in 2019 alone [4].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and its senior executives for potential violations of federal securities laws, following disappointing financial results and issues with its melanoma treatment, Amtagvi [1][2][5]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and high patient drop-off rates due to ineffective patient identification and selection [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates [5]. - Following the announcement of these results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly misleading investors about its business prospects, particularly regarding the launch dynamics of its cell therapy product, Amtagvi [1][2]. Company Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a significant decline [3]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated revenue forecast reflects challenges with the growth trajectories and treatment timelines for new Authorized Treatment Centers (ATCs) [3]. Allegations and Investigation - The lawsuit alleges that Iovance failed to disclose critical issues, including longer timelines for new ATCs to begin treating patients, inefficiencies in patient identification and selection, and the resulting higher costs and lower revenues [2]. - The complaint claims that these undisclosed factors rendered the company's positive statements about its business and prospects materially misleading [2]. Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud that negatively impacted investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].